Simcere Pharmaceutical Group Reports Third Quarter 20...(captured 100% of the fast-growing inject...),Health

Date:11/5/2007

captured 100% of the fast-growing injectable edaravone market, where Bicun focused primarily on the premium edaravone market while Boda's Yidasheng on the medium to low end. This strategic acquisition is a good example of our product based M&A strategy, which helps slow down competition pressure for our biggest seller Bicun, while ensuring Simcere's leading position and strong growth momentum in capturing the whole edaravone market. We believe this will help to maintain the company's high gross margin and high profitability characteristics.

We are confident that we will meet our 2007 full year performance guidance. Our team will continue to work hard to ensure that Simcere maintains its position as a leading player in the Chinese pharmaceutical industry."

2007 Third Quarter and Nine Month Financial Results

Total revenue for the third quarter of 2007 was RMB323.4 million (US$43.2 million), representing an increase of 44.5% from RMB223.8 million for the same period in 2006. For the first nine months of 2007, total revenue was RMB990.6

million (US$132.2 million), representing an increase of 42.4% from RMB695.5 million for the same period in 2006.

Revenue from Endu, the Company's patented anti-cancer biotech drug launched in July 2006, totaled RMB52.8 million (US$7.1 million) in the third quarter of 2007, representing 16.4% of the Company's product revenue for the quarter and an increase of 377.3% from RMB11.1 million in the corresponding period in 2006. For the first nine months of 2007, revenue from Endu totaled RMB152.2 million (US$20.3 million), representing 15.8% of product revenue.

Revenue from Bicun, the Company's first-to-market stroke management product, totaled RMB106.2 million (US$14.2 million) in the third quarter of 2007. In the third quarter, Bicun's revenue represented 32.9% of the company's product revenue compared to 25.8% in the prior year period, and demonstrated an increase of 83.8% from RMB57.8 million in the cor
'/>"/>

SOURCE Simcere Pharmaceutical Group Copyright©2007 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13
Related medicine news :

1. Simcere Pharmaceutical Group Acquires a 51% Stake in Boda Pharmaceutical Co., Ltd.
2. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
3. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
4. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
5. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
6. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
7. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
8. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
9. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
10. Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts Meeting September 28, 2007
11. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences